ABBV-992 / AbbVie - LARVOL DELTA

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: AbbVie | N=105 ➔ 5 | Trial completion date: May 2023 ➔ Jan 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: May 2023 ➔ Jan 2023; Strategic considerations

Adverse events • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers (clinicaltrials.gov) - P1 | N=5 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Jan 2023 ➔ May 2023 | Trial primary completion date: Jan 2023 ➔ May 2023

Adverse events • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology